NR1H4 and atherosclerosis: These tuberatolides were potent (1.5–2.5 μM) antagonists of chenodeoxycholic acid-activated human farnesoid X receptor (hFXR), and this fact may help to unravel the controversial function of FXR in atherosclerosis.